Bortezomib has shown synergy with melphalan in preclinical models. We assessed the safety, tolerability, and response rate in a dose-escalation study of this combination for relapsed or refractory multiple myeloma patients.
INTRODUCTION
Multiple myeloma (MM) remains an aggressive and incurable malignancy. The combination of melphalan plus prednisone (MP) is used commonly to treat symptomatic myeloma but results in a median survival of only 3 years. 1, 2 Combination chemotherapy has improved response rates, but an improvement in survival relative to MP has not been demonstrated. 3 The addition of thalidomide to MP may improve survival. 4 The only therapy that has clearly demonstrated an improvement in survival compared with conventional chemotherapy as first-line treatment is high-dose chemotherapy followed by stem-cell transplantation, 5, 6 an option unavailable to many elderly patients or those with pre-existing medical conditions. Despite this advance, nearly all patients will experience relapse and require additional treatment, highlighting the need for more effective and tolerable therapies.
The proteasome inhibitor bortezomib (Velcade; Millennium Pharmaceuticals Inc, Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development LLC, New Brunswick, NJ) was approved recently in the United States and European Union as a second-line treatment for MM patients.
7,8 Bortezomib 1.3 mg/m 2 on days 1, 4, 8, and 11 of a 21-day cycle for up to eight cycles in patients with relapsed and refractory myeloma in the phase II Study of Uncontrolled Multiple Myeloma Managed with Proteasome Inhibition Therapy (SUMMIT) trial achieved a response rate (complete response [CR] or partial response [PR] ) of 27% using the European Group for Blood and Marrow Transplantation criteria, 9 a median duration of response of 13 months, 10,11 and a median overall survival of 17 months. 11 In another phase II trial, the Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST), patients who experienced relapse after or were refractory to first-line treatment were randomly assigned to bortezomib 1.0 or 1.3 mg/m 2 using the same schedule. The lower dose was clinically active (CR ϩ PR ϭ 30%) and well tolerated. 12 The most clinically important adverse effect of bortezomib has been peripheral neuropathy (PN), and patients receiving bortezomib 1.0 mg/m 2 in CREST had an incidence of PN of 21% compared with 62% in patients receiving bortezomib 1.3 mg/m 2 . 12 Thus, lower doses of bortezomib have the potential to offer activity with less toxicity. A phase III trial (the Assessment of Proteasome Inhibition for Extending Remissions [APEX]) in myeloma patients experiencing relapse after one to three prior therapies demonstrated superiority of bortezomib over dexamethasone in response rate, time to progression, and overall survival. 13 In APEX, which recommended specific dose modification guidelines for PN, the incidence of PN was 36% with bortezomib.
Lower doses of melphalan may offer clinical utility because myelosuppression is the major dose-limiting toxicity of this alkylating agent. In vitro, exposure of highly melphalan-resistant myeloma cell lines, as well as bone marrow tumor cells from myeloma patients, to noncytotoxic concentrations of bortezomib increased sensitivity to melphalan, but this was not observed in normal bone marrow stem cells or peripheral-blood lymphocytes. 14, 15 This dose-escalation clinical study evaluated the safety, tolerability, and activity of bortezomib and melphalan among patients with relapsed or refractory MM, starting with lower doses of both agents in an effort to reduce the incidence and severity of toxicities and to develop a potentially synergistic effect of this combination.
METHODS

Patients
Patients with relapsed or refractory MM with active progression after receiving Ն two prior treatment regimens were eligible for enrollment. Inclusion criteria included age Ն 18 years, measurable disease, Karnofsky performance status Ն 60%, creatinine clearance Ն 30 mL/min, and a life expectancy Ն 3 months. 16 Patients were excluded if they had received chemotherapy Յ 3 weeks before enrollment, had a baseline platelet count Յ 50,000/L (or Յ 30,000/L if thrombocytopenia was disease related), hemoglobin Յ 8 g/dL, absolute neutrophil count Յ 1,000/L, serum hepatic aminotransferase levels Ն 3ϫ the upper limit of normal or a total serum bilirubin Ն 2ϫ the upper limit of normal, or any other serious medical illness that could potentially interfere with the completion of treatment.
The Cedars-Sinai and Western institutional review boards approved the treatment protocol, and a written, informed consent was signed by all patients before participation in the study. This study was conducted in accord with the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice.
Study Design and Drug Administration
The primary objectives of the study were to determine the response rate and evaluate the safety profile and tolerability of this combination in patients using a 28-day schedule. Secondary objectives were to assess the time to response and progression-free survival.
In the first five cohorts, enrolled patients received a fixed dose of intravenous bolus bortezomib 0.7 mg/m 2 on days 1, 4, 8, and 11 of a 28-day cycle for a maximum of eight cycles. Oral melphalan was administered in escalating doses from 0.025, 0.05, 0.10, and 0.15 mg/kg, to a maximal dose of 0.25 mg/kg, on days 1 to 4 of the 28-day cycle. Three patients were enrolled onto each cohort. The next three cohorts received a fixed dose of bortezomib 1.0 mg/m 2 and escalating doses of melphalan (0.025, 0.10, and 0.25 mg/kg) on the same schedule. After the first patient completed a full cycle without a dose-limiting toxicity (DLT), the remaining two patients were enrolled onto that cohort. Dose escalation continued if no DLT was observed after all three patients completed a 28-day cycle. If a DLT was observed in two or more patients at any dose level, an additional three patients were recruited at the previous dose level.
DLT was defined as any grade 4 neutropenia, thrombocytopenia, or anemia. Grade 3 thrombocytopenia with grade 3 or 4 hemorrhage, grade 3 or 4 nausea and vomiting refractory to antiemetic therapy, and any other nonhematologic toxicity grade Ն 3 during the first cycle of therapy were considered DLTs. The maximum-tolerated dose (MTD) was defined as the highest dose level atwhichfewerthantwoofsixpatients(33%)experiencedaDLT.Patientswhohad not experienced disease progression after eight cycles were eligible to receive bortezomib 1.3 mg/m 2 alone every 2 weeks in a maintenance phase of the protocol.
Pretreatment and Safety Assessments
Pretreatment evaluations consisted of patient history and physical examination, ECG, and chest radiographs. Neurologic examinations were conducted by the study physicians at screening, the beginning of each cycle, and study conclusion. Vital signs were measured at screening, before and after each intravenous treatment, and at the end of the study. Adverse events were assessed per the National Cancer Institute Common Toxicity Criteria, version 2.0.
17 Blood samples were collected at screening and before each intravenous treatment, reviewed before administration of treatment, and collected again at the end of the study. Urine samples were tested at screening and at every other cycle. A negative pregnancy test was required for all women of childbearing potential.
Response Criteria
Patients were monitored for response after each treatment cycle by quantitation of serum immunoglobulins, serum protein electrophoresis, immunofixation, and collection of a 24-hour urine specimen for total protein, electrophoresis, and immunofixation. Response was evaluated using European Group for Blood and Marrow Transplantation criteria after cycle 2 and successive cycles.
9 CR was defined as a negative immunofixation test for myeloma protein in serum and urine on at least two determinations for a minimum of 6 weeks, the absence of soft-tissue plasmacytomas, no increase in the size of lytic bone lesions, and less than 5% plasma cells in the marrow. Immunofixation (IF) -positive CR was defined as meeting all the criteria of CR except that the immunofixation test was positive. PR was defined as a Ն 50% reduction of serum M-protein in at least two determinations 6 weeks apart and, if present, reduction in 24-hour urinary light-chain excretion by either Ն 90% or to less than 200 mg. Minimal response (MR) was defined as a 25% to 49% reduction of serum M-protein and, if present, reduction in urine M-protein by 50% to 89%. PR or MR required no increase in the size of lytic bone lesions and a decrease in the size of soft-tissue plasmacytomas. Progressive disease (PD) was defined as either a more than 25% increase of M-protein in serum or urine or an increase in the size and number of lytic bone lesions or plasmacytomas. Bone marrow aspirate and biopsy were required for patients who achieved CR or demonstrated PD.
Time to response was defined as the time from first treatment until at least MR was observed. Progression-free survival was defined as the time during and after treatment that a patient maintained a response or stable disease.
RESULTS
Patients and Dose Escalation
Thirty-five patients were enrolled between August 1, 2002, and January 3, 2005, and follow-up was until June 15, 2005. Patient and disease characteristics are listed in Table 1 .
Fifteen of the 29 patients enrolled onto the first seven cohorts received the maximum eight cycles (32 weeks) of treatment. Eleven patients discontinued prematurely because of PD, including three patients in cohort 6, two patients each in cohorts 1 and 7, and one patient each in cohorts 2, 3, 4, and 5. Treatment of patients in cohorts 7 and 8 is ongoing in five patients, and only two patients (in cohort 8) had to discontinue treatment prematurely because of PD.
Treatment-Emergent Toxicities
Adverse events are listed in Table 2 . No DLT was observed in the first five cohorts. The first DLT (grade 4 anemia) occurred in cohort 6 (bortezomib 1.0 mg/m 2 , melphalan 0.025 mg/kg), which was then expanded to include four additional patients. The patient with DLT discontinued because of prolonged hospitalization, osteomyelitis, and multiple bone fractures. No additional DLTs were observed in the expanded cohorts 6 or 7. In cohort 8 (bortezomib 1.0 mg/m 2 , melphalan 0.25 mg/kg), grade 4 pancytopenia (lasting Ͻ 7 days and not accompanied by fever or infection) occurred in one patient. When this cohort was expanded by three additional patients, another patient experienced grade 4 neutropenia (lasting 4 weeks and accompanied by acute herpes zoster infection). Therefore, bortezomib 1.0 mg/m 2 and melphalan 0.1 mg/kg were determined to be the MTD.
Myelosuppression was the most common grade 3 toxicity. Grade 3 neutropenia, thrombocytopenia, and anemia occurred in roughly equal proportions overall but were more frequent in the higher-dose cohorts. Fifty-two percent of the instances of grade 3 cytopenia occurred in patients who had a baseline cytopenia. In 10 patients, doses of one or both agents were withheld or reduced because of transient cytopenias: one because of anemia accompanied by fever (cohort 7); one because of neutropenia accompanied by fever (cohort 1); two because of thrombocytopenia alone (cohorts 4 and 5); three because of neutropenia alone (cohorts 6 and 8 [two patients in cohort 8]); two because of both neutropenia and thrombocytopenia (cohorts 4 and 6); and one because of neutropenia, thrombocytopenia, and anemia (cohort 2). No serious bleeding was observed, and only one patient with grade 4 thrombocytopenia required a platelet transfusion (cohort 8). Sixteen of 35 patients (46%) received erythropoietin, seven of 35 patients (20%) received packed RBCs, and one patient received granulocyte colony-stimulating factor.
In addition to neuropathy (see the next paragraph), nonhematologic toxicities primarily were GI (nausea, 63%; vomiting, 34%; diarrhea, 37%; and constipation, 29%) and manageable with routine intervention. Cough (37%), fatigue (71%), pyrexia (26%), and rash (29%) were reported frequently. None of the nonhematologic toxicities showed a clear relationship to the melphalan dose. Four patients required doses to be withheld because of nonhematologic toxicities: one each because of flu-like symptoms accompanied by an erythematous rash (cohort 1), increased serum creatinine and blood urea nitrogen (cohort 1), rash with pruritus (cohort 5), and PN (cohort 6). When PN was observed in cycle 5 in this latter patient, the bortezomib dose was reduced to 0.7 mg/m 2 . Treatment-emergent PN occurred in 11 patients (31%) but was grade 1 or 2 in all except one patient. In the limited follow-up to date, PN resolved in three of 11 patients and remained stable in the rest. Among the 15 patients who had baseline grade 1 or 2 neuropathy at study entry, the symptoms of neuropathy remained stable in 11 patients, resolved in one patient, and worsened in only three patients (Table 3) . In one patient, the dose of bortezomib was reduced to 0.7 mg/m 2 because of neuropathic symptoms. Of the patients without baseline neuropathy (n ϭ 20), eight developed grade 1 or 2 neuropathy during the study, including two of nine patients (22%) who received bortezomib 0.7 mg/m 2 and six of 11 patients (55%) who received bortezomib 1.0 mg/m 2 . Of the patients who did not have baseline neuropathy, none required treatment to be reduced, withheld, or discontinued.
Efficacy
Overall, responses were achieved in 23 of 34 assessable patients (68%), including two with CR (6%), three with IF-positive CR (9%), 11 with PR (32%), and seven with MR (21%). Eight patients (24%) had stable disease, all of whom had shown PD at the time of study entry. One patient in cohort 7 died before receiving the first treatment cycle and was not assessable. Responses were observed in five of six patients (83%) at the MTD (1.0 mg/m 2 bortezomib and 0.1 mg/kg melphalan). In 10 of 23 responding patients (43%), responses were observed during the first two treatment cycles. Median time to response was 3 months (range, 2 to 8 months), and median progression-free survival for all patients was 8 months (range, 2 to 18 months). The pattern of response by cohort and by patient is summarized in Table 4 . Responses were observed regardless of type of prior treatment (Table 5) .
Responses were observed in all cohorts, although only MRs were observed among patients in cohorts 2 and 4. Among patients achieving PR, one patient was in cohort 3, and two patients each were in cohorts 1, 5, 6, 7, and 8. IF-positive CR was observed in two patients in cohort 7 and in one patient in cohort 8. CR was achieved in one patient each in cohorts 6 and 8. Fifty-eight percent of patients (11 of 19) receiving the higher dose of bortezomib (1.0 mg/m 2 ; cohorts 6 to 8) achieved Ն PR, compared with only 33% of patients (five of 15) receiving the lower dose (0.7 mg/m 2 ; cohorts 1 to 5). 
Maintenance Phase
After completing eight cycles of bortezomib and melphalan, 12 patients entered the maintenance phase, receiving bortezomib 1.3 mg/m 2 as monotherapy every 2 weeks without melphalan. These patients were treated for an additional median of three cycles (range, one to eight cycles) with bortezomib alone, although two patients remain on treatment. The reasons patients did not receive maintenance therapy after achieving a response included inconvenience and PD.
DISCUSSION
The activity of bortezomib as monotherapy for patients with relapsed and/or refractory MM is well established.
10-13 On the basis of preclinical observations, 14, 16, 18, 19 treatment of myeloma with bortezomib in combination with other agents has been investigated clinically. Bortezomib in combination with dexamethasone was evaluated in phase II trials. 20 Other studies include bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies, 21 and bortezomib plus thalidomide plus dexamethasone in patients with myeloma relapsing after autologous transplantation. 22 In the first-line setting, bortezomib is being evaluated alone, in combination with dexamethasone, and in combination with dexamethasone and thalidomide or doxorubicin or with MP, with and without stem-cell transplantation.
23-28
The doses of bortezomib in this study, 0.7 and 1.0 mg/m 2 given on days 1, 4, 8, and 11 of a 4-week schedule, represent 40% and 57%, respectively, of the dose-intensity per month administered in the SUMMIT trial, 10 in which 1.3 mg/m 2 was given four times during a 3-week cycle. 29 The starting dose of melphalan at 0.025 mg/kg in cohort 1 is 10% of the amount that is generally used in conventional treatment regimens for myeloma patients. In this study, lower doses of bortezomib (0.7 to 1.0 mg/m 2 ) plus oral melphalan for patients with refractory or relapsed myeloma were active with predictable and manageable toxicities. The observation that seven of 13 patients who previously were treated with melphalan responded to the combination (including two patients who previously were refractory to melphalan) supports clinically the in vitro observation that bortezomib can overcome chemotherapy resistance. 14, 15 More studies are needed before this conclusion is established firmly.
The antimyeloma activity of low-dose melphalan and bortezomib was encouraging, given that all patients had relapsed or were 32  PR  2  2  2  33  SD  NA  7  7ϩ  34  CR  5  6  6ϩ  35  SD  NA  2  3 Abbreviations: CR, complete response; IFϩ, immunofixation positive; MR, minimal response; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease.
‫ء‬
Maintenance therapy with bortezomib may have influenced progression-free survival. refractory to previous treatments and had progressive disease at enrollment. Previous studies evaluating oral melphalan at higher doses in combination with glucocorticoids in this clinical setting have produced disappointing results, with low response rates. 30 In contrast, 23 of 34 assessable patients (68%) responded in this trial (ie, achieved CR, IF-positive CR, PR, or MR). Time to response generally was rapid and responses were observed at all dose levels. However, all CRs or IFpositive CRs were observed among patients who received bortezomib 1.0 mg/m 2 , and achievement of PR or better also was higher among these patients (55% at bortezomib 1.0 mg/m 2 , compared with 33% at the 0.7 mg/m 2 dose level). This response rate was higher than would be expected with bortezomib alone at 1.0 mg/m 2 ; the CR ϩ PR rate among patients who received bortezomib at this dose was only 30% in the CREST trial.
12 Although, the impact of the maintenance phase is not clear, a phase III trial evaluating the importance of bortezomib as maintenance therapy is ongoing.
31
Myelosuppression was the DLT of this regimen, but was not associated with major clinical toxicity such as febrile neutropenia or sepsis. In patients treated with bortezomib 1.0 mg/m 2 in CREST, thrombocytopenia occurred in 32% of patients (including grade 3 in 29%), whereas neutropenia and anemia occurred in 11% and 21% of patients, respectively.
12 In addition, melphalan potentially is more myelotoxic when combined with bortezomib 1.0 mg/m 2 than when used alone. Two patients receiving the highest dose of melphalan (0.25 mg/kg) developed grade 4 cytopenias, although this toxicity was not observed at doses Յ 0.1 mg/kg. Melphalan potentially is more myelosuppressive at higher doses than bortezomib at the dose of 1.0 mg/m 2 . Since single-agent bortezomib at higher doses (1.3 mg/m 2 ) is effective in approximately one third of patients, 10 its efficacy may also improve when low-dose melphalan is added, as demonstrated in this study. It will be important to study future clinical experience of this combination with this higher bortezomib dose.
Treatment-emergent PN was observed in 11 of 35 patients (31%), and occurred more frequently among the patients who received the higher dose of bortezomib. However, only one patient developed grade 3 (who had baseline neuropathy) and none developed grade 4 neuropathy. Previous trials have shown a higher incidence of severe neuropathy with bortezomib. 10, 12 In the SUMMIT trial, 12% of patients developed grade 3 neuropathy but none developed grade 4 neuropathy. 10 A similar proportion of patients (15%) receiving the 1.3 mg/m 2 dose in the CREST trial developed grade 3 neuropathy but no patient experienced grade 4 neuropathy, whereas patients receiving the 1.0 mg/m 2 had a lower incidence of grade 3 or 4 neuropathy (7%). In addition, 10% of the patients discontinued the CREST trial because of neurotoxicity, 12 whereas none of the patients discontinued this trial because of treatment-related neuropathy. The rate of grade Ն 3 PN was also lower than that in the APEX trial (8%). Bortezomib was administered with a 10-day rest in these studies, whereas the rest period was 17 days in our study. The longer rest period may have contributed to the lower incidence of severe (grade Ն 3) treatment-emergent PN, but it did not reduce the overall incidence of this adverse event compared with previous trials.
Melphalan-based regimens continue to be an important foundation of care in newly diagnosed and relapsed/refractory myeloma. The combination of prednisone and a lower dose of melphalan (4 mg/m 2 ), with and without thalidomide 100 mg daily, is under investigation. 4 In this ongoing study in an older patient population, thalidomide improved response rate, but the high rate of adverse events, particularly deep venous thrombosis, necessitated discontinuation of thalidomide in more than one third of the patients. Anticoagulation therapy may increase the safety of this combination. Preliminary results of a phase II trial of melphalan (9 mg/m 2 ) and prednisone (60 mg/m 2 ) plus bortezomib (1.3 mg/m 2 ) in elderly, previously untreated patients with myeloma seem promising.
28
Thus far, this combination has been well tolerated, and all assessable patients have achieved a response. Therefore, additional dose escalation of bortezomib to 1.3 mg/m 2 with melphalan alone may be warranted. An ongoing phase III trial, is comparing MP with and without bortezomib in the first-line treatment of MM in patients who are not transplantation candidates.
Although MP is commonly used in patients with newly diagnosed myeloma, the lack of a glucocorticoid is another advantage of the melphalan/bortezomib combination in addition to its high response rate. Many patients with relapsed or refractory disease are resistant to these agents and tolerate them poorly at the time of PD, with significant adverse effects that affect their quality of life. [32] [33] [34] Bortezomib and melphalan are individually active in myeloma, and when administered together (at lower than generally recommended doses) in this study, were active in relapsed or refractory MM with manageable toxicity. This combination may be suitable for elderly patients with comorbidities. Importantly, responses were observed among patients who experienced treatment failure after a wide variety of prior treatments, including bortezomib, thalidomide, and lenalidomide. Because of the encouraging findings in this trial and the establishment of an MTD, a phase II clinical trial of this combination regimen for patients with newly diagnosed MM has been recently initiated. 
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